GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krsnaa Diagnostics Ltd

Krsnaa Diagnostics Q2 FY27 Revenue up 32% to INR 2,710 Mn

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 06:46 PM IST  ·  BSE ID: d5eb1c81-c795-4090-a89f-2d20350570e1
View Original BSE Filing (PDF)
💡
In Simple Terms
Krsnaa Diagnostics saw its quarterly sales increase by 32% to INR 2,710 Mn, serving more patients and conducting more tests.
🤖 AI Summary
  • Consolidated revenue from operations reached INR 2,710 Mn in Q2 FY27, marking a 32% year-on-year increase.
  • EBIDTA stood at INR 719 Mn for Q2 FY27, reflecting a 20% year-on-year growth.
  • Profit After Tax (PAT) for Q2 FY27 was INR 246 Mn, increasing 3% compared to Q2 FY26.
  • The number of tests performed grew by 85% to 30.3 Mn, and patients served increased by 35% to 7.3 Mn.
  • NABH accredited radiology centers expanded by 108% to 75 in Q2 FY27 from 36 in Q2 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations
2,710 Mn
32%
EBIDTA
719 Mn
20%
EBIDTA Margin
27%
2%
PAT
246 Mn
3%
PAT Margin
9%
3%
No. of Test Performed
30.3 Mn
85%
No. of Patient Served
7.3 Mn
35%
NABH Accreditation (Radiology Centre)
75
108%
🏢 How This Affects the Company
📈
Business Impact
The company's revenue growth indicates an expanded market presence and increased patient engagement, supported by a significant rise in tests performed and patients served.
💰
Financial Impact
Revenue increased by INR 650 Mn YoY, while EBIDTA margins compressed by 2% to 27% and PAT margins by 3% to 9%, impacted by upfront fixed costs from new Rajasthan laboratories.
⚙️
Operational Impact
Operational capacity increased significantly, evidenced by the 85% rise in tests performed and a 108% increase in NABH accredited radiology centers to 75.
⚠️
Risk Impact
The moderation in margins due to upfront fixed costs suggests a short-term pressure on profitability as new facilities in Rajasthan are yet to reach full utilization.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this results presentation.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with the Q2 FY27 PAT at INR 246 Mn impacting earnings per share calculations.
🔍
Management Signal
Management is focused on expanding its network and capacity, as evidenced by the 108% increase in NABH accredited radiology centers to 75 and new projects in Rajasthan.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for sustained revenue growth and margin trends.
Updates on utilization rates of new Rajasthan laboratories to assess margin recovery.
Further expansion announcements and their impact on operational capacity.
MEDIUM RISK Margin moderation due to upfront fixed costs of new facilities poses a short-term profitability risk.
💡 Investor Takeaway
Krsnaa Diagnostics reported Q2 FY27 consolidated revenue of INR 2,710 Mn, up 32% YoY. EBIDTA increased 20% to INR 719 Mn, while PAT rose 3% to INR 246 Mn. Margins saw moderation, with EBIDTA margin at 27% and PAT margin at 9%, attributed to upfront fixed costs for new Rajasthan laboratories.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations grew by 32% year-on-year to INR 2,710 Mn in Q2 FY27, indicating strong top-line performance.
  • Number of tests performed increased by 85% to 30.3 Mn and NABH accredited centers by 108% to 75, demonstrating significant operational expansion.

⚠️ Concerns

  • EBIDTA margin compressed by 2% to 27% in Q2 FY27, partly due to upfront fixed costs from new Rajasthan laboratories.
  • PAT margin decreased by 3% to 9% in Q2 FY27, impacting overall profitability despite revenue growth.
📅 Company Track Record
Krsnaa Diagnostics previously reported Q2 FY27 revenue grew 31.54% to INR 2,709.69 Million on November 02, 2026. The board had met on November 02, 2026, to approve Q2 and half-year FY27 results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Krsnaa Diagnostics' consolidated revenue from operations in Q2 FY27?
Krsnaa Diagnostics reported consolidated revenue from operations of INR 2,710 Mn in Q2 FY27, representing a 32% increase year-on-year.
What was the EBIDTA and PAT for Krsnaa Diagnostics in Q2 FY27?
The EBIDTA for Krsnaa Diagnostics in Q2 FY27 was INR 719 Mn, and the PAT was INR 246 Mn. EBIDTA grew by 20% YoY, while PAT increased by 3% YoY.
How did Krsnaa Diagnostics' margins perform in Q2 FY27?
EBIDTA margin for Krsnaa Diagnostics in Q2 FY27 was 27%, down 2% from Q2 FY26. PAT margin was 9%, a 3% decrease from the previous year, attributed to upfront fixed costs for Rajasthan laboratories.
How many tests did Krsnaa Diagnostics perform and patients serve in Q2 FY27?
Krsnaa Diagnostics performed 30.3 Mn tests and served 7.3 Mn patients in Q2 FY27, representing year-on-year increases of 85% and 35% respectively.
What was the change in NABH accredited radiology centers for Krsnaa Diagnostics?
NABH accredited radiology centers for Krsnaa Diagnostics increased to 75 in Q2 FY27, up 108% from 36 in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.